The Motley Fool··Adria CiminoCRISPR Therapeutics Eyes $223B Autoimmune Market With Gene-Editing Breakthrough
CRISPR Therapeutics leverages FDA-approved gene editing to target a $223B autoimmune disease market, positioning itself as the post-GLP-1 growth opportunity in biotech.
LLYVRTXNVOCRSPclinical trialsgene therapy